Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026

Published by KBV Research Product code 988519
Published Content info 64 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026
Published: January 29, 2021 Content info: 64 Pages
Description

The North America Biodefense Market would witness market growth of 5% CAGR during the forecast period (2020-2026).

Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.

Bioterrorism refers to the utilization of biological agents that are damaging the mankind. Biodefense means the usage of medical steps in order to save mankind from bioterrorism, including interventions like drugs and vaccinations. Moreover, research and public health preparations have seen development to counter biological attacks. Some of the past incidents of bioterrorism carried out by viral agents like botulism, anthrax, and smallpox, have made biodefense a significant focus area for research by countries to defend against bioterrorism.

Governments' agencies were forced to develop and strategize biodefense programs due to repeated outbreaks of the Ebola and Zika virus, hence aid in planning and responding during future outbreaks. In 2018, the U.S. government issued the National Biodefense Strategy to manage the threats of biological incidents by identifying and preventing bio treats at its initial stage, encouraging biomedical innovation, and enhancing emergency response.

Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.

Scope of the Study

Market Segmentation:

By Product

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/nuclear,
  • Other Products

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • Xoma Corporation
  • Altimmune, Inc.
  • Emergent BioSolutions, Inc.
  • Dynavax Technologies Corporation
  • SIGA Technologies, Inc.
  • Elusys Therapeutics, Inc.
  • Ichor Holdings, Ltd.
  • Cleveland BioLabs, Inc.
  • Bavarian Nordic A/S
  • Alnylam Pharmaceuticals, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Biodefense Market, by Product
    • 1.4.2 North America Biodefense Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 Recent Industry Wide Strategic Developments
    • 3.1.1 Partnerships, Collaborations and Agreements
    • 3.1.2 Approvals
    • 3.1.3 Acquisition and Mergers
  • 3.2 Top Winning Strategies
    • 3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players

Chapter 4. North America Biodefense Market by Product

  • 4.1 North America Anthrax Market by Country
  • 4.2 North America Smallpox Market by Country
  • 4.3 North America Botulism Market by Country
  • 4.4 North America Radiation/nuclear Market by Country
  • 4.5 North America Other Product Market by Country

Chapter 5. North America Biodefense Market by Country

  • 5.1 US Biodefense Market
    • 5.1.1 US Biodefense Market by Product
  • 5.2 Canada Biodefense Market
    • 5.2.1 Canada Biodefense Market by Product
  • 5.3 Mexico Biodefense Market
    • 5.3.1 Mexico Biodefense Market by Product
  • 5.4 Rest of North America Biodefense Market
    • 5.4.1 Rest of North America Biodefense Market by Product

Chapter 6. Company Profiles

  • 6.1 Xoma Corporation
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Altimmune, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Research & Development Expense
    • 6.2.4 Recent strategies and developments:
      • 6.2.4.1 Acquisition and Mergers:
      • 6.2.4.2 Partnerships, Collaborations, and Agreements:
  • 6.3 Emergent BioSolutions, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Research & Development Expense
    • 6.3.4 Recent strategies and developments:
      • 6.3.4.1 Acquisition and Mergers:
      • 6.3.4.2 Partnerships, Collaborations, and Agreements:
  • 6.4 Dynavax Technologies Corporation
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Research & Development Expense
  • 6.5 SIGA Technologies, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Research & Development Expense
    • 6.5.4 Recent strategies and developments:
      • 6.5.4.1 Partnerships, Collaborations, and Agreements:
      • 6.5.4.2 Approvals:
  • 6.6 Elusys Therapeutics, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Recent strategies and developments:
      • 6.6.2.1 Approvals:
  • 6.7 Ichor Holdings, Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Partnerships, Collaborations, and Agreements:
  • 6.8 Cleveland BioLabs, Inc.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Research & Development Expense
    • 6.8.4 Recent strategies and developments:
      • 6.8.4.1 Partnerships, Collaborations, and Agreements:
  • 6.9 Bavarian Nordic A/S
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Partnerships, Collaborations, and Agreements:
      • 6.9.5.2 Approvals:
  • 6.10. Alnylam Pharmaceuticals, Inc.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Research & Development Expense

LIST OF TABLES

  • TABLE 1 North America Biodefense Market, 2016 - 2019, USD Million
  • TABLE 2 North America Biodefense Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Biodefense Market
  • TABLE 4 Approvals- Biodefense Market
  • TABLE 5 Acquisition and Mergers- Biodefense Market
  • TABLE 6 North America Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 7 North America Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 8 North America Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 9 North America Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 10 North America Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 11 North America Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 12 North America Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 13 North America Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 14 North America Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 15 North America Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 16 North America Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 17 North America Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 18 North America Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 19 North America Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 20 US Biodefense Market, 2016 - 2019, USD Million
  • TABLE 21 US Biodefense Market, 2020 - 2026, USD Million
  • TABLE 22 US Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 23 US Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 24 Canada Biodefense Market, 2016 - 2019, USD Million
  • TABLE 25 Canada Biodefense Market, 2020 - 2026, USD Million
  • TABLE 26 Canada Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 27 Canada Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 28 Mexico Biodefense Market, 2016 - 2019, USD Million
  • TABLE 29 Mexico Biodefense Market, 2020 - 2026, USD Million
  • TABLE 30 Mexico Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 31 Mexico Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 32 Rest of North America Biodefense Market, 2016 - 2019, USD Million
  • TABLE 33 Rest of North America Biodefense Market, 2020 - 2026, USD Million
  • TABLE 34 Rest of North America Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 35 Rest of North America Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 36 Key Information -Xoma Corporation
  • TABLE 37 Key Information - Altimmune, Inc.
  • TABLE 38 Key Information - Emergent BioSolutions, Inc.
  • TABLE 39 Key Information - Dynavax Technologies Corporation
  • TABLE 40 Key Information - SIGA Technologies, Inc.
  • TABLE 41 key information - Elusys Therapeutics, Inc.
  • TABLE 42 key Information - Ichor Holdings, Ltd.
  • TABLE 43 Key Information - Cleveland BioLabs, Inc.
  • TABLE 44 key information - Bavarian Nordic A/S
  • TABLE 45 Key Information - Alnylam Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players
  • FIG 4 Recent strategies and developments: Altimmune, Inc.
  • FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.
Back to Top